Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.004170%
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.021126%Not Available
Drug interaction08.06.03.0010.015289%Not Available
Dysarthria17.02.08.001; 19.19.03.0010.005560%
Dyspepsia07.01.02.001--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.002780%Not Available
Encephalopathy17.13.02.0010.031689%
Eosinophilia01.02.04.0010.008339%
Epilepsy17.12.03.0020.002780%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.005560%
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.006949%
Faeces discoloured07.01.03.0020.002780%Not Available
Failure to thrive14.03.02.008; 19.07.05.001; 18.04.01.0030.006115%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Feeling drunk08.01.09.0150.004170%Not Available
Flatulence07.01.04.002--
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastrointestinal disorder07.11.01.0010.019180%Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.002780%
Generalised tonic-clonic seizure17.12.01.0020.051425%Not Available
Glomerulonephritis minimal lesion20.05.01.0110.006949%Not Available
Glossodynia07.14.02.001--Not Available
Glycosuria20.02.01.0050.002780%
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene